Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma
Background Immunotherapy emerged as a promising treatment option for multiple myeloma (MM) patients.However, therapeutic efficacy can be hampered by the presence of an immunosuppressive bone marrow microenvironment including myeloid cells.S100A9 was previously identified as a key regulator of myeloid cell accumulation and suppressive activity.Tasqu